HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers.

Abstract
The STARD3 gene belongs to the minimal amplicon in HER2-positive breast cancers and encodes a cholesterol-binding membrane protein. To study how elevated StAR-related lipid transfer protein 3 (StARD3) expression affects breast cancer cells, we generated MCF-7 cells stably overexpressing StARD3-green fluorescent protein. We found that StARD3-overexpressing cells exhibited nonadherent morphological features, had increased Src levels, and had altered cholesterol balance, as evidenced by elevated mRNA levels of the cholesterol biosynthesis rate-limiting enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and increased plasma membrane cholesterol content. On removal of serum and insulin from the culture medium, the morphological characteristics of the StARD3-overexpressing cells changed, the cells became adherent, and they developed enlarged focal adhesions. Under these conditions, the StARD3-overexpressing cells maintained elevated Src and plasma membrane cholesterol content and showed increased phosphorylation of focal adhesion kinase. In two Finnish nationwide patient cohorts, approximately 10% (212/2220) breast cancers exhibited high StARD3 protein levels, which was strongly associated with HER2 amplification; several factors related to poor disease outcome and poor breast cancer-specific survival. In addition, high StARD3 levels in breast cancers were associated with elevated 3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA levels and anti-Src-Tyr416 immunoreactivity. These results provide evidence that StARD3 overexpression results in increased cholesterol biosynthesis and Src kinase activity in breast cancer cells and suggest that elevated StARD3 expression may contribute to breast cancer aggressiveness by increasing membrane cholesterol and enhancing oncogenic signaling.
AuthorsBoris Vassilev, Harri Sihto, Shiqian Li, Maarit Hölttä-Vuori, Jaakko Ilola, Johan Lundin, Jorma Isola, Pirkko-Liisa Kellokumpu-Lehtinen, Heikki Joensuu, Elina Ikonen
JournalThe American journal of pathology (Am J Pathol) Vol. 185 Issue 4 Pg. 987-1000 (Apr 2015) ISSN: 1525-2191 [Electronic] United States
PMID25681734 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Carrier Proteins
  • Insulin
  • Membrane Proteins
  • RNA, Messenger
  • STARD3 protein, human
  • Green Fluorescent Proteins
  • Cholesterol
  • Hydroxymethylglutaryl CoA Reductases
  • Receptor, ErbB-2
  • src-Family Kinases
Topics
  • Animals
  • Breast Neoplasms (metabolism, pathology)
  • Carrier Proteins (metabolism)
  • Cell Adhesion (drug effects)
  • Cell Membrane (drug effects, metabolism)
  • Cell Shape (drug effects)
  • Cholesterol (metabolism)
  • Disease Progression
  • Enzyme Activation (drug effects)
  • Female
  • Focal Adhesions (drug effects, metabolism)
  • Gene Amplification (drug effects)
  • Green Fluorescent Proteins (metabolism)
  • Humans
  • Hydroxymethylglutaryl CoA Reductases (genetics, metabolism)
  • Insulin (pharmacology)
  • MCF-7 Cells
  • Membrane Proteins (metabolism)
  • Middle Aged
  • Phosphorylation (drug effects)
  • RNA, Messenger (genetics, metabolism)
  • Rabbits
  • Receptor, ErbB-2 (metabolism)
  • Serum (metabolism)
  • src-Family Kinases (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: